DAWN

Company Overview — What Does Day One Biopharmaceuticals, Inc. Do?

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Day One Biopharmaceuticals, Inc. (DAWN) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jeremy Bender and employs approximately 60 people. With a market capitalization of $2.2B, DAWN is one of the notable companies in the Healthcare sector.

Day One Biopharmaceuticals, Inc. (DAWN) Stock Rating — Hold (April 2026)

As of April 2026, Day One Biopharmaceuticals, Inc. receives a Hold rating with a composite score of 38.0/100 and 3 out of 5 stars from the Blank Capital Research quantitative model.DAWN ranks #1,896 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Day One Biopharmaceuticals, Inc. ranks #200 of 838 stocks, placing it in the top quartile of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

DAWN Stock Price and 52-Week Range

Day One Biopharmaceuticals, Inc. (DAWN) currently trades at $21.47. The stock lost $0.01 (0.0%) in the most recent trading session. The 52-week high for DAWN is $21.43, which means the stock is currently trading 0.2% from its annual peak. The 52-week low is $5.63, putting the stock 281.0% above its annual trough. Recent trading volume was 456K shares, suggesting relatively thin trading activity.

Is DAWN Overvalued or Undervalued? — Valuation Analysis

Day One Biopharmaceuticals, Inc. (DAWN) carries a value factor score of 27/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 5.02x, versus the sector average of 2.75x. The price-to-sales ratio is 11.18x, compared to 1.66x for the average Healthcare stock.

At current multiples, Day One Biopharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Day One Biopharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

Day One Biopharmaceuticals, Inc. (DAWN) earns a quality factor score of 14/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -14.8%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -12.9% versus the sector average of -33.1%.

On a margin basis, Day One Biopharmaceuticals, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -66.5% (sector: -66.1%). Net profit margin stands at -51.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 385.8% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

DAWN Debt, Balance Sheet, and Financial Health

Day One Biopharmaceuticals, Inc. has a debt-to-equity ratio of 15.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 8.02x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $43M.

DAWN has a beta of 0.77, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Day One Biopharmaceuticals, Inc. is 35/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Day One Biopharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Day One Biopharmaceuticals, Inc. reported revenue of $198M and earnings per share (EPS) of $-1.04. Net income for the quarter was $-65M. Gross margin was 100.0%. Operating income came in at $-71M.

In FY 2025, Day One Biopharmaceuticals, Inc. reported revenue of $158M and earnings per share (EPS) of $-1.04. Net income for the quarter was $-107M. Revenue grew 20.6% year-over-year compared to FY 2024. Operating income came in at $-128M.

In Q3 2025, Day One Biopharmaceuticals, Inc. reported revenue of $40M and earnings per share (EPS) of $-0.19. Net income for the quarter was $0. Revenue grew -57.6% year-over-year compared to Q3 2024. Operating income came in at $-24M.

In Q2 2025, Day One Biopharmaceuticals, Inc. reported revenue of $34M and earnings per share (EPS) of $-0.29. Net income for the quarter was $-30M. Revenue grew 313.9% year-over-year compared to Q2 2024. Operating income came in at $-35M.

Over the past 8 quarters, Day One Biopharmaceuticals, Inc. has demonstrated a growth trajectory, with revenue expanding from $8M to $198M. Investors analyzing DAWN stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

DAWN Dividend Yield and Income Analysis

Day One Biopharmaceuticals, Inc. (DAWN) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

DAWN Momentum and Technical Analysis Profile

Day One Biopharmaceuticals, Inc. (DAWN) has a momentum factor score of 71/100, indicating strong price momentum with the stock outperforming the majority of the market over recent periods. Stocks with high momentum scores have historically tended to continue their outperformance in the near term. The investment factor score is 21/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 64/100 reflects moderate short selling activity.

DAWN vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Day One Biopharmaceuticals, Inc. (DAWN) ranks #200 out of 838 stocks based on the Blank Capital composite score. This places DAWN in the top quartile of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing DAWN against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full DAWN vs S&P 500 (SPY) comparison to assess how Day One Biopharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

DAWN Next Earnings Date

No upcoming earnings date has been announced for Day One Biopharmaceuticals, Inc. (DAWN) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy DAWN? — Investment Thesis Summary

Day One Biopharmaceuticals, Inc. presents a balanced picture with arguments on both sides. The quality score of 14/100 flags below-average profitability. The value score of 27/100 indicates premium valuation. Price momentum is positive at 71/100, suggesting the trend favors buyers. High volatility (stability score 35/100) increases portfolio risk.

In summary, Day One Biopharmaceuticals, Inc. (DAWN) earns a Hold rating with a composite score of 38.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on DAWN stock.

Related Resources for DAWN Investors

Explore more research and tools: DAWN vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare DAWN head-to-head with peers: DAWN vs AZN, DAWN vs SLGL, DAWN vs VMD.